Open Orphan Plc (GB:HVO) has released an update.
Open Orphan Plc has launched its expanded hLAB services, now offering an enhanced suite of virology and immunology laboratory services for drug development, following the recent capacity upgrade at its Canary Wharf facility. The company’s CL-3 lab has received Health & Safety Executive clearance, enabling work with high-risk pathogens, and hLAB has also introduced a biobank approved by the UK Research Ethics Committee. Additionally, hLAB will be present at the World Vaccine Congress in Barcelona, showcasing their expanded capabilities to the vaccine development community.
For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.
